Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Simes

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study GroupE Beller, M Tattersall, T Lumley, et al.
JAMA|May 24, 1995
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesF Van de Werf, E J Topol, K L Lee, et al.
Circulation|March 1, 1996
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trialC B Granger, J Hirsch, R M Califf, et al.
Lancet (London, England)|July 11, 2001
Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trialG Lawrence, D Tudehope, K Baumann, et al.
American Heart Journal|June 1, 1997
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I InvestigatorsR M Califf, L H Woodlief, F E Harrell, et al.
European Heart Journal|April 2, 2002
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionF Zijlstra, A Patel, M Jones, et al.
The New England Journal of Medicine|August 3, 2000
Pravastatin therapy and the risk of strokeH D White, R J Simes, N E Anderson, et al.
Lancet (London, England)|March 20, 2001
Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial GroupG C Toner, M R Stockler, M J Boyer, et al.
BMC Cardiovascular Disorders|March 10, 2022
Common genetic variants do not predict recurrent events in coronary heart disease patientsP L Thompson, J Hui, J Beilby, et al.
British Journal of Cancer|July 14, 2011
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerC K Lee, H Gurney, C Brown, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1997
Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study GroupE Beller, M Tattersall, T Lumley, et al.
JAMA|May 24, 1995
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary ArteriesF Van de Werf, E J Topol, K L Lee, et al.
Circulation|March 1, 1996
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trialC B Granger, J Hirsch, R M Califf, et al.
Lancet (London, England)|July 11, 2001
Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trialG Lawrence, D Tudehope, K Baumann, et al.
American Heart Journal|June 1, 1997
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I InvestigatorsR M Califf, L H Woodlief, F E Harrell, et al.
European Heart Journal|April 2, 2002
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarctionF Zijlstra, A Patel, M Jones, et al.
The New England Journal of Medicine|August 3, 2000
Pravastatin therapy and the risk of strokeH D White, R J Simes, N E Anderson, et al.
Lancet (London, England)|March 20, 2001
Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial GroupG C Toner, M R Stockler, M J Boyer, et al.
BMC Cardiovascular Disorders|March 10, 2022
Common genetic variants do not predict recurrent events in coronary heart disease patientsP L Thompson, J Hui, J Beilby, et al.
British Journal of Cancer|July 14, 2011
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerC K Lee, H Gurney, C Brown, et al.
Pageof 15